February 6, 2026
Climbing out-of-the-hole
Earnings: Arrowhead Pharmaceuticals (ARWR) <in the Bottom line>
Pre-open Signals: 5 Positive Indications; appears to be an uplifting “prognosis” today; If you understand probabilities, the inevitable is easier to maneuver
Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.
Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t!
February 4, 2026
SGMO continues to fall -$0.0168 or -4.31% to $0.37
Proceeds are estimated at $25 M
SGMO closed <Monday> at $0.5679 and is trading at -$0.1413 or -24.74% to $0.44
Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering.
The offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock.
February 5, 2026
As sector earnings begin (IQV in The Bottom Line>, while tech/software shares decline; the C> sector rout increases
What you as an investor need to know, and what’s behind the curtain of dropping LPS (loss-per-share) share pricing
Pre-open Indications: 2 Hits
RMi collects, curates, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision
Never leave a retail investor uninformed! It’s not always time to buy or sell; but it is time to KNOW why!
February 4, 2026
SGMO continues to fall -$0.0168 or -4.31% to $0.37 Proceeds are estimated at $25 M SGMO closed <Monday> at $0.5679 and is trading at -$0.1413 or -24.74% to $0.44 Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering. The offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock.
January 25, 2026
AXGN closed +$0.83 or +2.59% to $32.83 with an aftermarket value of +$0.16 or +0.49% Having increased the deal from US$85 million to US$124 M, with the funds earmarked for debt repayment, working capital, and general corporate uses. The gross proceeds expected to be approximately $124 M (assuming no exercise of the underwriters’ option expecting to close on 1/23/26, subject to the satisfaction of customary closing conditions.
January 21, 2026
Another Opinion: Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? https://finance.yahoo.com/news/fda-no-trial-stance-deramiocel-111135647.html I am NOT the only DISSENTER! s Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump. https://finance.yahoo.com/news/capricor-therapeutics-capr-still-attractive-052444220.html FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process. CAPR expects to submit updates to the BLA in February 2026 to support continued FDA review. As previously disclosed, CAPR provided topline results from its P3 HOPE-3 clinical study to the FDA in late 2025. Rejected for more data. For all my … <some say> … RANTINGS, I say TRUTH … timing will be everything until the FDA “speaks;” the higher CAPR rose from 12/2’s $6.36, the steeper the fall! STICKING to my CONVICTION that Capricor Therapeutics (CAPR) is overbought and whose valuation is disconnected from fundamentals.
9 hours ago
RMi Pre-opening: Ricochet
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
